Associated Papers
A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants.
Aboulkassim T et al.
Cell Reports, 2023
KEAP1 Cancer Mutants: A Large-Scale Molecular Dynamics Study of Protein Stability.
Wilson CJ et al.
International Journal of Molecular Sciences, 2021
Molecular effects of cancer-associated somatic mutations on the structural and target recognition properties of Keap1.
Khan H et al.
The Biochemical Journal, 2015
25582950 (PubMed )
Supplement: supplement_1.pdf
Select a paper to view details